IN8BIO, INC. Logo

IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for cancer.

INAB | US

Overview

Corporate Details

ISIN(s):
US45674E1091
LEI:
Country:
United States of America
Address:
EMPIRE STATE BUILDING, 10118 NEW YORK

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform utilizes allogeneic, autologous, and genetically modified approaches to develop novel cell therapies. IN8BIO was the first to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400, a Phase 2 asset for newly diagnosed glioblastoma (GBM), and INB-100, a Phase 1 candidate for patients with leukemia undergoing hematopoietic stem cell transplantation. The company is also advancing a broad portfolio of preclinical programs focused on solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BRISTOL MYERS SQUIBB CO Logo
A global biopharmaceutical company that discovers, develops, and commercializes medicines.
United States of America
BMY
An R&D-focused company developing drugs for CNS disorders and oncology.
South Korea
003000
C4 Therapeutics, Inc. Logo
Clinical-stage biopharma developing targeted protein degradation therapeutics.
United States of America
CCCC
Cadrenal Therapeutics, Inc. Logo
A late-stage biopharmaceutical company developing novel anticoagulation therapeutics.
United States of America
CVKD
CalciMedica, Inc. Logo
Develops CRAC channel inhibitors for acute inflammatory and immunologic diseases.
United States of America
CALC
Calidi Biotherapeutics, Inc. Logo
Develops stem cell platforms to deliver oncolytic viruses for cancer therapy.
United States of America
CLDI
Calliditas Therapeutics Logo
Biopharma company developing and commercializing treatments for rare diseases.
Sweden
CALTX
CALTH. Inc Logo
Develops in vitro diagnostic tools for point-of-care and self-testing.
South Korea
402420
Cambrex Logo
A CDMO providing drug substance, drug product, and analytical services.
United States of America
CBM
CAMBRIDGE NUTRITIONAL SCIENCES PLC Logo
Develops and manufactures diagnostic tests for food sensitivity and gut health.
United Kingdom
CNSL

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.